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ABSTRACT
Fibrous dysplasia (FD) is a skeletal disease caused by somatic activating mutations of the cyclic adenosine monophosphate (cAMP)-
regulating protein, a-subunit of the Gs stimulatory protein (Gsa). These mutations lead to replacement of normal bone by proliferative
osteogenic precursors, resulting in deformity, fracture, and pain. Medical treatment has been ineffective in altering the disease course.
Receptor activator of NF-kB ligand (RANKL) is a cell-surface protein involved in many cellular processes, including osteoclastogenesis,
and is reported to be overexpressed in FD-like bone cells. Denosumab is a humanized monoclonal antibody to RANKL approved for
treatment of osteoporosis and prevention of skeletal-related events from bone metastases. We present the case of a 9-year-old boy
with severe FD who was treated with denosumab for a rapidly expanding femoral lesion. Immunohistochemical staining on a
pretreatment bone biopsy specimen revealed marked RANKL expression. He was started on monthly denosumab, with an initial starting
dose of 1mg/kg and planned 0.25mg/kg dose escalations every 3 months. Over 7 months of treatment he showed marked reduction in
pain, bone turnover markers (BTMs), and tumor growth rate. Denosumab did not appear to impair healing of a femoral fracture that
occurred while on treatment. With initiation of treatment he developed hypophosphatemia and secondary hyperparathyroidism,
necessitating supplementation with phosphorus, calcium, and calcitriol. BTMs showed rapid and sustained suppression. With
discontinuation there was rapid and dramatic rebound of BTMs with cross-linked C-telopeptide (reflecting osteoclast activity) exceeding
pretreatment levels, accompanied by severe hypercalcemia. In this child, denosumab lead to dramatic reduction of FD expansion and
FD-related bone pain. Denosumab was associated with clinically significant disturbances of mineral metabolism both while on treatment
and after discontinuation. Denosumab treatment of FD warrants further study to confirm efficacy and determine potential morbidity,
as well as to determine the mechanism of RANKL in the pathogenesis of FD and related bone marrow stromal cell diseases.  2012
American Society for Bone and Mineral Research.
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Introduction
Fibrous dysplasia (FD; OMIM 174800) is an uncommon skeletaldisorder in which normal bone and bone marrow are
replaced by fibro-osseous tissue, leading to fracture, functional
impairment, deformity, and pain.(1–3) FDmay occur in association
with cutaneous hyperpigmentation and hyperfunctioning
endocrinopathies, including hyperthyroidism, precocious puber-
ty, growth hormone excess, and Cushing syndrome.(4–6) Skeletal
lesions produce excess fibroblast growth factor 23 (FGF23),
leading to renal phosphate wasting, hypophosphatemia, and
rickets/osteomalacia in individuals with high disease burden.(7,8)
FD in combination with one or more extraskeletal manifestations
is termed McCune-Albright syndrome (MAS).
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FD/MAS arises from activating missense mutations of the
GNAS gene, which encodes the a-subunit of the Gs stimulatory
protein (Gsa).
(9,10) Mutations occur postzygotically, resulting in a
mosaic pattern of disease.(11,12) There is wide variability in both
the combination of tissues involved and the extent of
involvement of affected tissue, likely arising from the fate of
the specific clones that harbor the mutation at the outset.(13) At
the cellular level, constitutive Gsa activation leads to increased
activity of adenylyl cyclase and excess production of intracellular
cyclic adenosine monophosphate (cAMP). In bone, the down-
stream effects of constitutively elevated Gsa lead to an inhibition
of differentiation and proliferation of bone marrow stromal cells
(BMSCs).(14–16) Normal bone is replaced with functionally and
structurally abnormal matrix, and marrow spaces show extensive
fibrosis with local loss of hematopoiesis. Recently, human
skeletal progenitor cells stably transfected with the FD-causing
R201C Gsa mutation were shown to dramatically upregulate
receptor activator of NF-kB ligand (RANKL) expression,(17)
consistent with the increased levels of osteoclastogenesis
observed in FD lesions in vivo.
Current medical treatment for FD is palliative. Surgery is often
necessary to mediate deformity and fracture, but is frequently
ineffective in the setting of severe disease.(18) Studies in
bisphosphonates have shown consistent improvements in FD-
related bone pain, but variable radiographic effects and no
apparent long-term benefit on overall clinical outcomes.(19–21)
Additional placebo-controlled trials are needed to further define
the role of bisphosphonates in treatment of FD; however, at
present their primary indication is limited to relief of FD-related
pain.
Denosumab is a fully-humanized monoclonal antibody to
RANKL recently approved for treatment of osteoporosis and
skeletal-related events in adults with bone metastases from solid
tumors.(22,23) RANKL is expressed by osteogenic cells including
osteoblasts, and plays a key role in osteoclastogenesis. By
binding to its receptor on osteoclast progenitor membranes,
RANKL promotes osteoclast differentiation and ultimately leads
to increased bone resorption. In addition to its role in
osteoclastogenesis, RANKL also plays a role in tumorigenesis
in both nonskeletal(24–27) and skeletal tissues.(28–30) Recent
evidence suggests that the development of skeletal neoplasms
depends upon activation of both RANKL and the cAMP/protein
kinase A.(31) RANKL inhibition via denosumab has recently been
shown to be effective in treatment of giant cell granulomas of
bone, which like FD are derived from BMSCs.(32)
Based upon lines of evidence presented above, RANKL
inhibition holds promise as a potential medical therapy for




A 9-year-old boy presented with extensive polyostotic FD,
hyperthyroidism, abnormalities on testicular ultrasound and
cafe´-au-lait macules, consistent with the diagnosis of MAS. The
FD in his right femur underwent a dramatic expansion over an
approximate 4-year period (Fig. 1). He was treated with
pamidronate for 1 year, which failed to slow expansion or
relieve associated bone pain. Femoral expansion was associated
with significant functional impairment, pain, and tachycardia
from increased cardiac output. At 8 years of age he underwent a
disarticulation amputation at the level of the femur-iliac joint.
Several months later the FD in his left femur began a similar
dramatic expansion, associated with significant bone pain
requiring daily narcotic use. A second disarticulation amputation
of his remaining lower extremity was planned. The patient’s
mother contacted the research team with hope that a treatment
might prevent the need for amputation.
A 12-month course of denosumab was planned in an attempt
to slow femoral expansion (Fig. 2A). The protocol was approved
by the Institutional Review Board of the NIDCR, and informed
assent and consent were obtained from the patient and his
mother. Denosumab was to be given once monthly, with an
initial starting dose of 1mg/kg. Dose escalations were planned at
3-month intervals to 1.25mg/kg, 1.5mg/kg, and 1.75mg/kg,
respectively. The starting dose was chosen as a dose intermedi-
ate between the dose used to treat osteoporosis (approximately
0.9mg/kg every 6 months) and the dose used to treat giant cell
tumor of bone (1.7mg/kg once monthly).
After 7 months of treatment the patient fell out of bed at home
and fractured his femur. The fracture occurred at the distal end of
an intramedullary rod, which served as a stress riser and a
predisposing site for fracture (Fig. 3A). Due to a theoretical risk of
delayed fracture healing, the eighth dose of denosumab was
held. Shortly thereafter the patient’s family lost contact with the
research team.
Fig. 1. Initial clinical presentation. (A) 99Technectium-MDP bone scan
showing extensive tracer uptake at multiple areas of FD and ballooning
expansion of the right femur (arrow). (B) X-ray shows massive expansion
of right femur and displacement of a rod that was originally in the
intramedullary canal. (C) Photograph showing classic ‘‘coast-of-Maine’’
cafe´-au-lait spots (arrow) and the effect of massive overgrowth of the
right femur. (D) CT at the level of the femura mid-shafts, with lateral
displacement of the rod on the right (white arrow), and an intramedullary
rod on the left (arrow head). The quadriceps muscles on the right have
been stretched to dysfunctional bands (), compared to the left ().
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Fig. 2. Proposed treatment regimen and clinical course. (A) Proposed regimen. Dosing regimen and monitoring schedule are indicated. Denosumab was
to be given monthly at an initial dose of 1mg/kg. Dose escalations were planned at 3-month intervals (arrows) to 1.25mg/kg, 1.5mg/kg, and 1.75mg/kg.
The patient was evaluated by his local endocrinologist monthly and at NIH every 3 months. Mineral panels were monitored weekly for the first 3 months
and then monthly (not shown). Bone turnover markers were monitored monthly (not shown). The scale represents months. D¼dose of denosumab;
TV¼ tumor volume; AS¼ arm span; XR¼hand XR; DE¼dental exam; BX¼bone biopsy. (B) Clinical course. The periods for the administration of
analgesics, supplemental phosphorus, calcium and calcitriol, denosumab, and bisphosphonate treatment (pamidronate or zoledronic acid) are indicated
by the transverse lines, and cessation by the double vertical lines. Time points for biopsy, fracture and start of hypercalcemia are indicated. The scale
represents months.
Fig. 3. Radiographs. (A) A radiograph at the time of fracture indicated the fracture occurred at the distal end of a previously inserted intramedullary rod
(arrow). (B) Radiograph taken 8 weeks after plate fixation shows callus formation at the fracture site (arrow). (C,D) Knee radiographs pretreatment and
6 months after the initiation of treatment, as indicated. (E,F) Hand radiographs, as above. Note the thick sclerotic bands at the level of the metaphyses in
panelsD and F (arrows), reminiscent of the radiologic appearance of children treated with bisphosphonates. There does not appear to be evidence of frank
rickets.
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Endpoints
The primary endpoint of denosumab efficacy was the rate of
change in tumor volume as measured by CT. Additional efficacy
endpoints were bone turnover markers (BTMs) and pain. Safety
endpoints were signs and symptoms of infection, effects on
dentition, and linear growth. Endpoints were assessed as
indicated in Fig. 2.
Lesion volume was assessed by a semiautomatic approach
using a Vitrea workstation (Vital Images Inc., Minnetonka, MN,
USA). An operator first placed a seed point inside the center of
the lesion. The computer program then learned the intensity and
texture pattern in the vicinity of the seed point and expanded
the region three-dimensionally to include pixels with similar
intensity and texture as that within the lesion. The lesion region
was then smoothed to close gaps and form a solid three-
dimensional (3D) object. The volume of the lesion was obtained
by counting the pixels inside the 3D object.
BTMs were measured for the formation marker procollagen
type 1 amino-terminal porpeptide (P1NP; Radioimmunoassay,
Mayo Medical Laboratories) and the resorption marker beta
cross-laps of type I collagen c-telopeptide-related fraction (B-
CTX; Electrochemiluminescence Immunoassay, Mayo Medical
Laboratories). Arm span was measured as a surrogate for linear
growth. Dental examinations, which included dental pano-
graphic and selected periapical radiographs to determine dental
development and morphology, were performed at baseline and
after 3 months of treatment.
RANKL immunohistochemistry was performed on paraffin-
embedded sections. Sections were deparaffinized and antigen
retrieval was performed using a heat-induced sodium citrate
buffer method. Primary antibody reaction was performed using a
monoclonal anti-RANKL antibody (Novus Biologicals, Littleton,
CO, USA; NB 100-56512) at 1 to 200 dilution incubated overnight
at 48C. Sections were then washed and incubated successfully
with the biotinylated secondary antibody (Vector Laboratories,
Burlingame, CA, USA; BA-9200) at 1 to 400 dilution for 30minutes
at room temperature. VECTASTAIN ABC method (Vector
Laboratories; PK-4000) was used and the slides were then
developed under direct microscopic visualization using Sigma-
Aldrich SIGMAFAST 3,30-diaminobenzidine (Sigma-Aldrich Corp.,
St. Louis, MO, USA; D4168).
Gsamutation testing was performed on BMSCs obtained from
a bone biopsy prior to treatment with denosumab. Single
colonies of cells were grown separately and total DNA was
isolated using Wizard genomic DNA isolation kit (Promega, WI,
USA). DNA from multiple colonies was PCR-amplified and
sequenced for subsequent Gsa genotyping. Total DNA was
isolated from individual BMSC colonies and used for amplifica-
tion reactions to enrich for the Gsa-specific genomic regions
using two specific oligonucleotides: 50-TGACTATGTGCCGAGC-
GATC-30 and 50-CCACGTCAAACATGCTGGTG-30. PCR products
were gel purified and were subsequently sequenced.
Results
Tumor volume
Tumor volume was assessed at four time points: 13.5 months
prior to initiation of denosumab, at the initiation of denosumab
treatment, and after 3 and 9 months of treatment. The volume of
FD in the left femur increased 57% between the initial scan and
the scan done at the start of denosumab (Fig. 4). Assuming a
linear rate of expansion over this 13.5-month period, tumor
volume increased at a rate of 4.2% per month. However, per
report of the patient’s mother and orthopedic surgeon, the
expansion began acutely and progressed rapidly over a 6-week
period immediately preceding the initiation of denosumab.
Assuming the tumor growth occurred during this 1.5-month
period, tumor volume increased at a rate of 37.7% per month
(Fig. 4C; dashed line). The rate of tumor growth was additionally
calculated after 3 and 9 months of treatment. During these
intervals the rate of growth was 1.4% per month and 0.56% per
month, respectively (Fig. 4C).
Additional endpoints
BTMs were significantly elevated at baseline, declined dramati-
cally after the first dose of denosumab, and remained suppressed
Fig. 4. Tumor volume. (A) A representative two-dimensional image created from a horizontal slice prior to denosumab treatment at the level of the
femoral head taken from a thin-slice CT study that was used tomeasure tumor volume (see Patient andMethods). (B) A similar image taken 2months after
the final dose of denosumab. (C) The change in tumor volume over time. The first and last time points were derived from the studies done for A and B. The
start of denosumab treatment is indicated. There were 13.5 months between the initial study and the scan done prior to start of denosumab. The solid line
represents the change in volume assuming a linear rate of growth. Per report of the patient’s mother and orthopedic surgeon, expansion began acutely
and progressed rapidly over 6 weeks prior to initiation of denosumab, represented by the dashed line. Initiation of treatment was associated with marked
decrease in the rate of tumor growth.
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throughout the duration of treatment (Fig. 5A, B). Narcotic-
requiring pain diminished dramatically after initiation of
denosumab. After one dose the patient was able to discontinue
narcotics in favor of ibuprofen, and after three doses was able to
stop analgesics altogether (Fig. 2). A dental exam was done at
baseline and 3 months after the start of denosumab treatment.
At baseline, healthy and normal dentition with mild dental
developmental delay was noted, and at follow-up, no deleterious
effects were seen. Hand radiographs were monitored every
3 months to assess for tubulation defects and deleterious effects
on the growth plate. The shapes of the bones were preserved,
and there were no obvious signs of rickets; however, the patient
developed thick sclerotic bands at the level of the metaphyses
(Fig. 3C–F).
A bone biopsy was obtained prior to treatment start, and
revealed sections of typical fibrous tissue and woven bone, but
also a striking abundance of cartilage that accounted for most of
the tissue in many sections. Osteoclasts were rare (Fig. 6A, B).
Immunohistochemical staining was markedly positive for RANKL
(Fig. 6C). Sequencing of DNA extracted from biopsy tissue and
PCR-amplified revealed a typical mutation in exon 8 of GNAS that
resulted in substitution of histidine for arginine at amino acid
position 201 (R201H) (Fig. 7).
The patient became hypophosphatemic with secondary
hyperparathyroidism shortly after receiving the first dose of
denosumab, necessitating supplementation with phosphorus,
calcitriol, and calcium. Blood phosphorus and calcium levels are
shown in Fig. 5C, D.
The patient underwent plate fixation of the left femur, and a
second biopsy specimen was obtained. The orthopedic surgeon
(FAF) reported the quality of the bone appeared to be
subjectively improved as compared to before denosumab
treatment. Samples were taken at the time of the surgery, but
the specimens were taken from areas of cortical bone and
comparison to pretreatment sections was not informative.
Radiographs taken 4 weeks after fixation showed callus
formation at the fracture site (Fig. 3B), and plans were being
made to resume denosumab, but due to unforeseen social issues
the patient was temporarily lost to follow-up.
Response to cessation of denosumab
Two months after the fracture and cessation of denosumab, the
patient presented to his local emergency department with
5 days of vomiting. Laboratory results revealed severe
hypercalcemia with a level of 4.5mmol/L (18mg/dL) (normal
2.1–2.6mmol/L). Phosphorus and creatinine were normal, and
parathyroid hormone (PTH), parathyroid hormone–related
protein (PTHrP), and 1,25-vitamin D were suppressed. BTMs
were extremely elevated. P1NP had returned to approximately
baseline levels, but B-CTX had rebounded to a level approxi-
mately 2.5-fold above the pretreatment level (Fig. 5A, B).
The patient was admitted to the hospital and treated with iv
hydration, calcitonin, and pamidronate. Calcium levels improved,
but he remained mildly hypercalcemic as an outpatient,
necessitating repeated treatment with intravenous bispho-
sphonates (pamidronate or zoledronic acid). BTMs gradually
returned to baseline after approximately 5 months (146 days)
following denosumab discontinuation, after which the hyper-
calcemia resolved.
Fig. 5. Biochemical response to treatment. (A) Serum B-CTX, a marker of bone resorption. (B) Serum P1NP, a marker of bone formation. (C) Serum calcium.
(D) Serum phosphorus. Denosumabwas initiated at day 0 and discontinued at day 210, indicated by the arrows. After discontinuation of denosumab there
was a marked increase in BTMs, especially the resorption marker CTX, which was associated with marked hypercalcemia in the presence of a suppressed
serum PTH, and 1,25(OH)2 vitamin D. Normal ranges for calcium and phosphorus are indicated by boxes. Normal ranges for CTX and P1NP in children are
not well defined.
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Discussion
In this child with a rapidly expanding FD lesion, treatment with
denosumabwas associated with a marked decrease in the rate of
tumor growth. Expansion of FD at this rate is a rare but
potentially devastating complication. Currently no medical
therapies are capable of altering the disease course of FD,
which makes this child’s response to RANKL inhibition of
particular interest. The mechanism by which this effect occurred
is not clear. The accepted mechanism of action of denosumab in
the treatment of osteoporosis is inhibition of osteoclastogenesis
by disruption of stromal cell/osteoblast–osteoclast RANK–RANKL
interaction. This may have been operative here, as osteoclastic
resorption of normal bone adjacent to FD is likely involved in
lesion expansion. In rapidly expanding lesions such as this,
stromal cell proliferation is likely the more important mechanism
of expansion. In osteoporosis, inhibition of osteoclastogenesis is
also accompanied by a concomitant and parallel inhibition of
bone formation, as evidenced by the marked decrease in
markers of bone formation, and marked inhibition of bone
formation as seen by histomorphometry.(23,33) In denosumab
treatment of giant cell granulomas, which like FD are tumors
composed primarily of fibroblast-like cells of BMSC lineage, there
is also inhibition of tumor growth.(32) Additionally, RANKL
inhibition has been shown to have direct inhibitory effects on
other tumors such as breast cancer.(24,25) Taken together, these
data suggest that denosumab treatment of FD may have direct
effects (or possibly indirect effects mediated by an as yet
unidentified osteoclast-derived factor) on the proliferating bone
marrow stromal-derived cells that dominate FD lesions.
Although promising, whether the response to denosumab
seen in this child will be replicated in other individuals with FD
remains to be seen. His presentation was atypical in both the
growth pattern (rapid onset and marked expansion), and
histologically. Specimens from both the amputated right leg
(not shown) and the lesionmonitored during treatment revealed
large areas of cartilaginous tissue and a relative paucity of
osteoclasts. Although small cartilaginous foci are not uncommon
in FD, extensive cartilaginous proliferation as seen here is a rare
but previously-described phenomenon.(34–36) The demonstra-
tion of a typical GNAS mutation in this lesion, the first time this
has been demonstrated in this variant of FD, confirms that
this molecular defect is at least partially responsible for the
Fig. 6. Histopathology. (A) An H&E stained section of FD taken prior to
the initiation of denosumab from a region of the lesion that demonstrat-
ed typical features of FD. The overall ‘‘Chinese character’’ appearance is
evident and consists of areas of typical fibrous tissue (FT) interspersed
among trabecular structures composed of woven bone (WB), as well as a
small region of relatively fatty bone marrow (M). (B) This H&E section was
from a region of the lesion that had a prominent cartilaginous compo-
nent (cart), as well as areas of FT composed of stromal cells and an area
with a myxoid appearance (myx), which again is sometimes seen in FD,
but is not typical. (C) A serial section adjacent to the area shown in B,
stained for RANKL, demonstrated that most of the stromal cells were
positive for RANKL, and that the chondroid cells were negative. The inset
panel on the right shows a high-power view of RANKL-positive stromal
cells and the inset panel on the left from a normal human lymph node
with RANKL-positive lymphoid cells served as a positive control for
RANKL staining.
Fig. 7. Mutation analysis. BMSCs were isolated from a pretreatment bone
biopsy and expanded in vitro, as described in Patient and Methods. Total
DNA was isolated and the mutated Gsa-specific region was amplified.
PCR products were sequenced, and DNA sequencing from the Arginine-
201 region is shown. Clonal strains carrying the wild-type Gsa (C G T) or
the heterozygous R201C mutation (C/T G T) are indicated by arrows.
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phenotype. However, the prominence of cartilage seen in this
specimen clearly marks the FD in this patient as atypical.
Whether or not denosumabwill have similar efficacy in typical FD
is not known; the fact that RANKL expression is prominent
in a model of FD(17) and that RANKL expression, as seen by
immunohistochemistry, can be seen in more histologically
typical FD lesions (personal observations, MTC), is encouraging
that it may.
The pretreatment rate of growth in this child was an estimate
based upon a combination of imaging data and observations of
the patient’s mother and orthopedist. This resulted in a degree of
uncertainty in determining the exact rate of growth and the
precise effect of denosumab treatment on the rate of growth.
Although it is possible that the lesion had undergone a
significant but time-limited period of expansion, and that the
initiation of denosumab was coincidental, this is probably less
likely than the possibility that denosumab had a direct effect on
lesion expansion. An effect by denosumab is supported by what
occurred in the right femur; ie, rapid and progressive expansion
until amputation. Additional studies are needed to assess
potential efficacy in FD.
Important and potentially serious side effects occurred as a
result of treatment with denosumab: secondary hyperparathy-
roidism and hypophosphatemia during denosumab treatment,
and severe hypercalcemia on discontinuation. The likely cause of
secondary hyperparathyroidism was combined inhibition of
osteoclast mediated calcium release from bone and FGF23-
mediated suppression of 1,25 (OH)2-vitamin D generation. As is
seen in extensive FD, serum FGF23 was elevated at 95.5 pg/mL
(normal 20–50 pg/mL), but FGF23 levels did not change
significantly throughout treatment. However, upon discontinua-
tion of denosumab there was a marked rebound in BTMs (CTX
rose to 2.5-fold greater than the pretreatment levels), with a
proportionally greater rebound in the resorption marker CTX
than the formation marker P1NP. BTM levels peaked at
approximately 90 days after denosumab discontinuation, and
returned to pretreatment levels after 146 days (approximately 5
months). Although a similar pattern of changes in BTMs has been
seen in patients with osteoporosis,(37) there are important
differences. Relative to patients with osteoporosis, there was a
similar marked and pronounced decline in both resorption and
formation markers. However upon discontinuation the rebound
was more rapid in this patient (3 months versus 6 months), the
rebound to levels above baseline was confined to the resorption
marker, the level of resorption marker rebound was much
greater (250% versus 60%), and the return to baseline was much
shorter (5 months versus 24 months). Of note, the rapidity
of return to baseline in this child was enhanced by treatment
with bisphosphonates. Hypercalcemia has not been previously
reported in association with denosumab discontinuation in
osteoporosis studies in which follow-up has been continued for
relatively long periods. Although hypercalcemia after denosu-
mab discontinuation has not been reported in cancer studies, in
which the doses are higher, adverse event monitoring is not as
long as the follow-up in osteoporosis studies. The marked
rebound seen in this patient may be due to some combination of
very active FD and a higher rate of bonemetabolism in a growing
child. Due to the severity of the associated adverse effects,
practitioners should be cautious in using denosumab in patients
with FD, and should consider limiting use to clinical trials and in
individuals with extremely severe disease.
Preclinical studies with denosumab in rodents and primates
demonstrated a significant inhibitory effect on linear growth and
tooth eruption.(38,39) In our patient there was no increase in arm
span over a 6-month period, which may represent impaired
linear growth as a complication of treatment. However, 6 months
is possibly too short of a period of time for determination of
growth velocity, and measurement of arm span in this patient
was technically difficult due to pain and impaired mobility. The
increase in primary spongiosa at the level of the epiphyses that
was observed as an area of sclerosis on the radiographs suggests
that growth was occurring. Nonetheless, growth impairment
should be monitored as a potential adverse effect of denosumab
in children. Hand and knee X-rays showed no clear impairment in
bone tubulation or geometry during the treatment period;
however, thick sclerotic bands developed at the level of the
metaphyses, consistent with profound suppression in bone
turnover. These findings are similar to those seen in children
treated with bisphosphonates,(40,41) and represent accumulation
of calcified cartilage from bisphosphonate-induced inhibition of
periepiphyseal cartilage resorption.
Although the femoral fracture that occurred while on
treatment was traumatic in nature, a contributory role of
denosumab treatment cannot be excluded. Atypical femur
fractures have been reported with antiresorptive treatment(42);
however, this typically only occurs after years of treatment. In
addition, fractures are a known complication of FD, and this
patient had sustained two previous FD-related femoral fractures
prior to treatment with denosumab. Consistent with what has
been seen in preclinical studies with denosumab, there was no
apparent disruption of fracture healing.(43)
Conclusions
In this child with FD, denosumab was effective for both
prevention of lesion expansion and FD-related bone pain.
Denosumab treatment was associated with predictable, clinically
significant side effects both during treatment (hypophosphate-
mia and secondary hyperparathyroidism) and on discontinua-
tion (hypercalcemia) that necessitated careful monitoring and
additional medications both during treatment and upon
discontinuation. Denosumab treatment of FD warrants further
study, not only to confirm efficacy and determine potential
morbidity, but also to study the mechanism of RANKL in the
pathogenesis of FD and related BMSC diseases.
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